Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Benitec has announced that a key patent focused on producing double-stranded nucleic acid constructs for therapeutic and related applications of RNA interference was granted in New Zealand.
Subscribe to our email newsletter
The granted claims of the patent include an invention directed towards producing constructs for RNA interference (RNAi) techniques. The invention provides a ribonucleic acid (RNA) for use as interfering RNA in gene silencing techniques to silence a target gene, the company said.
The patent is also pending in a number of other jurisdictions and the company expects further grants in the coming months.
Sue MacLeman, CEO of Benitec, said: “This is an excellent example of a patent that offers broad coverage and leverage in the field of RNAi therapeutics. We have already licensed this patent family for use in preclinical and clinical development of a hepatitis C therapeutic construct and will look to further licensing opportunities.”